Results 191 to 200 of about 20,711,708 (259)

Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial (OXB‐102/Axo‐Lenti‐PD) in People with Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background SUNRISE‐PD was a dose‐escalating, phase 1/2 study investigating a second‐generation lentiviral vector gene therapy delivering the genes for dopamine synthesis (OXB‐102) to treat Parkinson's disease (PD). The trial was prematurely terminated due to insolvency of the sponsor.
Simon Rowe, Amy Evans, Saeed Kayhanian, Philip C. Buttery, Robert Morris, Katie Andresen, Laura Sherlock, Samuel Hewitt, Tagore Nakornchai, Marwan Hariz, Kyriacos Mitrophanous, Ludvic Zrinzo, Matthew Appleby, Phil Woodgate, Seema Maru, Patricia Limousin, Christine Girges, Thomas Foltynie, Stephane Palfi, Roger A. Barker   +19 more
wiley   +1 more source

Five-year outcomes from a multi-center prospective randomized controlled trial of minimally invasive interspinous fixation versus open direct decompression for lumbar spinal stenosis. [PDF]

Interv Pain Med
Baranidharan G, Bretherton B, Feltbower RG, Timothy J, Khan AL, Subramanian A, Ahmed M, Crowther TA, Radford H, Gupta H, Chandramohan M, Beall DP, Deer TR, Hedman T, Rogers A, Huxman C.   +15 more
europepmc   +1 more source

A Gap Analysis of Deep Brain Stimulation for Childhood‐Onset Movement Disorders

Movement Disorders, EarlyView.
Abstract Background Deep brain stimulation (DBS) is an established and increasingly utilized therapy for childhood‐onset movement disorders. However, pediatric DBS poses unique challenges that are not adequately addressed by adult‐derived paradigms. Objective To identify key gaps in the current use of DBS in childhood‐onset movement disorders and to ...
Daniela Munoz‐Chesta, Carolina Gorodetsky, Todd M. Herrington, Angela L. Hewitt, Daniel E. Lumsden, Jennifer O'Malley, Terence Sanger   +6 more
wiley   +1 more source

Reply to: Malik MMUD on Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT). [PDF]

Int Forum Allergy Rhinol
Mullol J, Han JK, Laidlaw TM, Hopkins C, Peters AT, Pfaar O, Desrosiers M, Lee SE, Lane AP, Chen C, Chon Y, Ponnarambil SS, Foster A, Lindsley AW, Ambrose CS.   +14 more
europepmc   +1 more source

Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study

Movement Disorders, EarlyView.
Abstract Background Pain is a common non‐motor symptom in Parkinson’s disease (PD) and is often associated to fluctuations. Objective The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) study evaluated the effect of opicapone on fluctuation‐related pain when added to levodopa therapy in PD patients.
Kallol Ray Chaudhuri, Joaquim J. Ferreira, Angelo Antonini, Olivier Rascol, Monica M. Kurtis, Alexander Storch, José‐Francisco Rocha, Raquel Costa, Diogo Magalhães, Guillermo Castilla‐Fernández, Helena C. Brigas, Joerg Holenz, Per Odin, on behalf of the OCEAN study group   +13 more
wiley   +1 more source

DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial. [PDF]

ESMO Gastrointest Oncol
Gordon A, Cartwright E, Tran A, Crux R, Turkes F, Smyth E, Smith A, Manalang I, Rana I, Kohoutova D, Johnston E, Dunlop A, Ul-Islam MS, Falk S, Sita-Lumsden A, Rao S, Starling N, Chau I, Cunningham D.   +18 more
europepmc   +1 more source

Rare‐Variant Burden across Lysosomal Genes Implicates Sialylation and Ganglioside Metabolism in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Lysosomal dysfunction is central to Parkinson's disease (PD) pathogenesis, with GBA1 representing the strongest established genetic risk factor. Numerous other genes involved in lysosomal sphingolipid, glycosphingolipid, and ceramide metabolism have been proposed as contributors to PD, highlighting the need for genetic analyses ...
Konstantin Senkevich, Sitki Cem Parlar, Cloe Chantereault, Lang Liu, Eric Yu, Uladzislau Rudakou, Jamil Ahmad, Jennifer A. Ruskey, Farnaz Asayesh, Dan Spiegelman, Cheryl Waters, Oury Monchi, Yves Dauvilliers, Nicolas Dupré, Lior Greenbaum, Sharon Hassin‐Baer, Irina Miliukhina, Alla Timofeeva, Anton Emelyanov, Sofya Pchelina, Roy N. Alcalay, Ziv Gan‐Or   +21 more
wiley   +1 more source

Correction to "Determinants of Healthcare Costs in Individuals With Down Syndrome: A Systematic Review". [PDF]

Health Sci Rep
europepmc   +1 more source

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial. [PDF]

Cancer
Stacchiotti S, Blay JY, Rutkowski P, Gelderblom H, Falcón A, Le Cesne A, Desai J, Palmerini E, Serrano C, Ganjoo KN, D'Amato GZ, Ryan CW, Wilky BA, Ferraresi V, Saleh R, Ravi V, Razak AA, Herráez AC, Ahmed M, Bernthal NM, van de Sande M, Brahmi M, Szostakowski B, Sen J, Zeringo NA, Harrow B, Narasimhan S, Saunders A, Sharma MG, Sherman ML, Wagner AJ, Tap WD.   +31 more
europepmc   +1 more source

Spatiotemporal Progression Patterns of Striatal Dopamine Depletion and Cerebral Hypoperfusion in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background The identification of Parkinson's disease (PD) subtypes is crucial for predicting the disease course and designing personalized therapeutic strategies. Objectives The aim of the study was to characterize the heterogeneity of the spatiotemporal evolutionary patterns of striatal dopamine depletion and cerebral hypoperfusion in PD ...
Yeeun Sun, Youngseok Choi, Chan Wook Park, Han Kyu Na, Hye Sun Lee, Yun Joong Kim, Young H. Sohn, Phil Hyu Lee, Jeyeon Lee, Seok Jong Chung   +9 more
wiley   +1 more source